A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (NCT07076199)
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
🩺 Plain-English Summary (8th-Grade Level)
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (9 items).
Location: Cullman Clinical Trials — Cullman, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Previous participation in this study. Participation is defined as signed informed consent.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Exposure to an investigational medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
- Any condition, except for conditions associated with type 1 diabetes mellitus, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- Anticipated initiation or anticipated change in concomitant medications (for more than 15 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with thyroid hormones, or systemic corticosteroids).
- Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question.
- Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (198 Sites)
Showing the first 25 of 198 sites.
- Cullman Clinical Trials — Cullman, Alabama
- John Muir Health — Concord, California
- Headlands Research California, LLC — Escondido, California
- Clinical Res of Central Ca — Fresno, California
- Providence Medical Foundation — Fullerton, California
- Scripps Whittier Diabetes Inst — La Jolla, California
- Loma Linda University Faculty Medical Clinics — Loma Linda, California
- Loma Linda University Faculty Medical Clinics — Loma Linda, California
- Pacific Clinical Studies — Los Alamitos, California
- Los Angeles Institute for Metabolic Research — Los Angeles, California
- Pasadena Clinical Trials — Pasadena, California
- WestenU Health — Pomona, California
- WestenU Health — Pomona, California
- Alliance Clinical Network — San Diego, California
- Mills Health Center — San Mateo, California
- Center for Endocrine DM and Metabolic Disorders — Santa Clarita, California
- University Clin Investigators — Tustin, California
- Diablo Clinical Research, Inc. — Walnut Creek, California
- Denver Endocrinology Diabetes and Thyroid Center — Englewood, Colorado
- Denver Endocrinology Diabetes and Thyroid Center — Englewood, Colorado
- Optumcare Clinical Trials,LLC-Golden — Golden, Colorado
- Northeast Research Institute — Fleming Island, Florida
- Encore Medical Research LLC — Hollywood, Florida
- Northeast Research Institute — Jacksonville, Florida
- Life Spring Research Foundation LLC — Miami, Florida
📞 Contact the Study Coordinator
Phone: (866) 867-7178
Email: clinicaltrials@novonordisk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus — Chicago, Illinois
- Healthy Outcomes for Muscle with Exercise in T1D — Hamilton, Ontario
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes — Orlando, Florida
- Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA — Montreal, Quebec
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.